bioAffinity's CyPath® Lung Sales Surge 146%; DoD Funds Major Clinical Trial
BIAF has more than doubled off its 52-week low of $0.693.
Summary
bioAffinity Technologies reported Q1 2026 results, highlighting a 146% year-over-year increase in CyPath® Lung unit sales and 114% revenue growth for the diagnostic, reaching $361,000. While total consolidated revenue decreased 27% to $1.4 million due to the strategic discontinuation of unprofitable pathology services, the company also announced a significant large-scale longitudinal clinical trial for CyPath® Lung, partially funded by the U.S. Department of Defense. This positive operational momentum, particularly the DoD-funded trial and strong core product growth, is highly material for this micro-cap company, especially following recent SEC filings regarding a potential reverse stock split and share resale, and a prior "going concern" warning. Traders will be watching for continued progress in the clinical trials and further acceleration of CyPath® Lung adoption to assess its impact on the company's long-term viability.
At the time of this announcement, BIAF was trading at $2.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $0.69 to $15.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.